Abiraterone vs docetaxel for metastatic castrate resistant prostate cancer

Dr Alibhai speaks with ecancertv at SIOG 2016 about the experience of men receiving abiraterone or docetaxel for the treatment of metastatic castrate resistant prostate cancer.

He discusses how the efficacy was similar to prior published studies, and how toxicities were slightly greater.

• #science_technology
• #abiraterone
• #docetaxel
• #metastatic
• #castrate
• #resistant
• #prostate
• #cancer